Cyclacel Pharma Financials
Financial Health Signals
Cyclacel Pharma passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Cyclacel Pharma generates $0.71 in operating cash flow (-$8.0M OCF vs -$11.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Cyclacel Pharma (CYCC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 27 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Cyclacel Pharma generated $43K in revenue in fiscal year 2024. This represents a decrease of 89.8% from the prior year.
Cyclacel Pharma's EBITDA was -$12.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.8% from the prior year.
Cyclacel Pharma reported -$11.2M in net income in fiscal year 2024. This represents an increase of 50.3% from the prior year.
Cyclacel Pharma earned $-504.30 per diluted share (EPS) in fiscal year 2024. This represents an increase of 92.1% from the prior year.
Cyclacel Pharma held $3.1M in cash against $0 in long-term debt as of fiscal year 2024.
Cyclacel Pharma had 36,913 shares outstanding in fiscal year 2024. This represents an increase of 736.7% from the prior year.
Cyclacel Pharma's operating margin was -27916.3% in fiscal year 2024, reflecting core business profitability. This is down 21856.0 percentage points from the prior year.
Cyclacel Pharma's net profit margin was -26074.4% in fiscal year 2024, showing the share of revenue converted to profit. This is down 20704.2 percentage points from the prior year.
Cyclacel Pharma invested $6.7M in research and development in fiscal year 2024. This represents a decrease of 65.3% from the prior year.
CYCC Income Statement
| Metric | Q3'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $81K | $0-100.0% | $10K+150.0% | $4K-86.2% | $29K-6.5% | $31K+93.8% | $16K-95.7% | $373K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $5K-99.4% | $880K-7.4% | $950K-53.0% | $2.0M-27.8% | $2.8M-20.4% | $3.5M-32.8% | $5.2M+10.8% | $4.7M |
| SG&A Expenses | $1.0M+5.9% | $948K-23.4% | $1.2M-23.9% | $1.6M+2.7% | $1.6M-15.5% | $1.9M+15.3% | $1.6M+3.2% | $1.6M |
| Operating Income | -$992K+45.7% | -$1.8M+16.0% | -$2.2M+40.3% | -$3.6M+16.3% | -$4.4M+18.8% | -$5.4M+21.7% | -$6.8M-15.4% | -$5.9M |
| Interest Expense | $9K | N/A | $8K+128.6% | -$28K-1500.0% | $2K | N/A | N/A | N/A |
| Income Tax | $2K-99.8% | $1.2M+668.6% | -$210K+49.0% | -$412K+69.6% | -$1.4M-220.9% | -$422K+36.8% | -$668K-14.0% | -$586K |
| Net Income | -$988K+67.6% | -$3.1M-56.0% | -$2.0M+39.9% | -$3.3M-10.6% | -$2.9M+44.1% | -$5.3M+12.6% | -$6.0M-10.7% | -$5.4M |
| EPS (Diluted) | $-1.31 | $-286.05 | $-43.80 | $-172.18-7485.0% | $-2.27 | N/A | N/A | $-0.44 |
CYCC Balance Sheet
| Metric | Q3'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.2M+99.3% | $4.1M-23.9% | $5.4M-34.3% | $8.2M+32.8% | $6.2M-30.0% | $8.8M-29.5% | $12.5M-26.4% | $17.0M |
| Current Assets | $6.4M+75.4% | $3.7M-25.2% | $4.9M-36.3% | $7.7M+59.4% | $4.8M-35.0% | $7.4M-33.0% | $11.1M-27.3% | $15.3M |
| Cash & Equivalents | $3.8M+22.3% | $3.1M+5.2% | $3.0M-50.3% | $6.0M+114.4% | $2.8M-17.2% | $3.4M-43.2% | $5.9M-41.5% | $10.2M |
| Inventory | $1.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $725K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $1.6M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.1M-83.1% | $6.3M-1.3% | $6.4M-11.7% | $7.2M-14.1% | $8.4M+2.1% | $8.2M0.0% | $8.2M+18.3% | $6.9M |
| Current Liabilities | $1.0M-84.0% | $6.3M-1.3% | $6.4M-11.6% | $7.2M-13.9% | $8.3M+2.3% | $8.2M+0.2% | $8.1M+18.7% | $6.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $7.1M+426.4% | -$2.2M-124.1% | -$970K-197.1% | $999K+145.3% | -$2.2M-463.4% | $607K-85.9% | $4.3M-35.6% | $6.7M |
| Retained Earnings | -$444.3M-1.1% | -$439.5M-0.7% | -$436.4M-0.5% | -$434.5M-0.8% | -$431.2M-0.7% | -$428.3M-1.2% | -$423.0M-1.4% | -$417.0M |
CYCC Cash Flow Statement
| Metric | Q3'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$434K+68.0% | -$1.4M+55.8% | -$3.1M+0.6% | -$3.1M-538.5% | -$483K+87.6% | -$3.9M+3.1% | -$4.0M-209.3% | -$1.3M |
| Capital Expenditures | N/A | N/A | $0 | N/A | N/A | $0 | $0 | $0 |
| Free Cash Flow | N/A | N/A | -$3.1M | N/A | N/A | -$3.9M+3.1% | -$4.0M-209.3% | -$1.3M |
| Investing Cash Flow | N/A | N/A | $0 | N/A | N/A | $0 | $0 | $0 |
| Financing Cash Flow | -$3K-100.2% | $1.6M+161400.0% | -$1K-100.0% | $6.3M+8060.8% | -$79K-107.9% | $999K+2098.0% | -$50K+2.0% | -$51K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CYCC Financial Ratios
| Metric | Q3'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1224.7% | N/A | -21770.0%+69330.0pp | -91100.0%-76082.8pp | -15017.2%+2273.1pp | -17290.3%+25490.9pp | -42781.3%-41191.7pp | -1589.5% |
| Net Margin | -1219.8% | N/A | -19570.0%+61855.0pp | -81425.0%-71266.4pp | -10158.6%+6844.6pp | -17003.2%+20696.8pp | -37700.0%-36239.4pp | -1460.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -12.1%+62.4pp | -74.6%-38.2pp | -36.4%+3.4pp | -39.8%+8.0pp | -47.8%+12.1pp | -59.9%-11.6pp | -48.3%-16.2pp | -32.1% |
| Current Ratio | 6.43+5.8 | 0.59-0.2 | 0.77-0.3 | 1.07+0.5 | 0.58-0.3 | 0.91-0.5 | 1.36-0.9 | 2.23 |
| Debt-to-Equity | 0.15+3.0 | -2.88+3.7 | -6.55-13.7 | 7.20+11.0 | -3.79-17.3 | 13.51+11.6 | 1.91+0.9 | 1.04 |
| FCF Margin | N/A | N/A | -30670.0% | N/A | N/A | -12612.9%+12612.1pp | -25225.0%-24875.1pp | -349.9% |
Note: Shareholder equity is negative (-$2.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.59), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Cyclacel Pharma's annual revenue?
Cyclacel Pharma (CYCC) reported $43K in total revenue for fiscal year 2024. This represents a -89.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cyclacel Pharma's revenue growing?
Cyclacel Pharma (CYCC) revenue declined by 89.8% year-over-year, from $420K to $43K in fiscal year 2024.
Is Cyclacel Pharma profitable?
No, Cyclacel Pharma (CYCC) reported a net income of -$11.2M in fiscal year 2024, with a net profit margin of -26074.4%.
What is Cyclacel Pharma's earnings per share (EPS)?
Cyclacel Pharma (CYCC) reported diluted earnings per share of $-504.30 for fiscal year 2024. This represents a 92.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Cyclacel Pharma's EBITDA?
Cyclacel Pharma (CYCC) had EBITDA of -$12.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cyclacel Pharma's operating margin?
Cyclacel Pharma (CYCC) had an operating margin of -27916.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Cyclacel Pharma's net profit margin?
Cyclacel Pharma (CYCC) had a net profit margin of -26074.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Cyclacel Pharma's operating cash flow?
Cyclacel Pharma (CYCC) generated -$8.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Cyclacel Pharma's total assets?
Cyclacel Pharma (CYCC) had $4.1M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Cyclacel Pharma spend on research and development?
Cyclacel Pharma (CYCC) invested $6.7M in research and development during fiscal year 2024.
How many shares does Cyclacel Pharma have outstanding?
Cyclacel Pharma (CYCC) had 36,913 shares outstanding as of fiscal year 2024.
What is Cyclacel Pharma's current ratio?
Cyclacel Pharma (CYCC) had a current ratio of 0.59 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Cyclacel Pharma's debt-to-equity ratio?
Cyclacel Pharma (CYCC) had a debt-to-equity ratio of -2.88 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cyclacel Pharma's return on assets (ROA)?
Cyclacel Pharma (CYCC) had a return on assets of -273.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Cyclacel Pharma's cash runway?
Based on fiscal year 2024 data, Cyclacel Pharma (CYCC) had $3.1M in cash against an annual operating cash burn of $8.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Cyclacel Pharma's debt-to-equity ratio negative or unusual?
Cyclacel Pharma (CYCC) has negative shareholder equity of -$2.2M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Cyclacel Pharma's Piotroski F-Score?
Cyclacel Pharma (CYCC) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cyclacel Pharma's earnings high quality?
Cyclacel Pharma (CYCC) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.